Boehringer Ingelheim Pharmaceuticals, Inc. 2023-03-29 Health serious FDA
Health · FDA · Recall #FDA-D-0468-2023
JARDIANCE (Empagliflozin), 25 mg Tablets, packaged in a) 30-count (NDC0597-0153-30) and… Recall
Issued March 29, 2023 · Boehringer Ingelheim Pharmaceuticals, Inc.
In March 2023, Boehringer Ingelheim Pharmaceuticals, Inc. recalled the JARDIANCE (Empagliflozin), 25 mg Tablets, packaged in a) 30-count (NDC0597-0153-30) and…, a serious health recall reported by the FDA.
Compiled by Maya Ellison, RecallCheckr
What this means for you
Labeling: Label Mix-up
What you should do
- 1 Stop using JARDIANCE (Empagliflozin), 25 mg Tablets, packaged in a) 30-count (NDC0597-0153-30) and… right away.
- 2 Set it aside where it won't be used by mistake.
- 3 Contact Boehringer Ingelheim Pharmaceuticals, Inc. to arrange your voluntary. See the official notice below for contact details.
- 4 Keep the product until your remedy is fully processed. You may need it.
Official remedy (Voluntary):
Recall details
- Brand
- Boehringer Ingelheim Pharmaceuticals, Inc.
- Category
- Health
- Recall date
- March 29, 2023
- Units affected
- Not reported
- Sold at
- Product was distributed nationwide within the United States and PR
- Recall number
- FDA-D-0468-2023
- Made in
- United States
- Issuing agency
- FDA
In context
- Boehringer Ingelheim Pharmaceuticals, Inc. has 1 recall in our database.
- We're tracking 3,576 Health recalls in our database.
- This is the 903rd Health recall we've logged in 2023.